To include your compound in the COVID-19 Resource Center, submit it here.

Myrexis discontinues Azixa

Myrexis Inc. (NASDAQ:MYRX) said it will discontinue development of Azixa verubulin, a small

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE